On January 20, 2025, U.S. President Donald Trump signed an executive order announcing the United States' withdrawal from the World Health Organization (WHO). The United Nations received this notification on January 22 of the same year. According to the WHO Constitution, a member state can formally withdraw one year after submitting its withdrawal application. January 22nd of this year marks the one-year anniversary of the United States formally submitting its application to withdraw from the World Health Organization to the United Nations. According to the WHO Constitution, This means that the United States has procedurally and formally withdrawn from the World Health Organization.

Recently, the EU unveiled a draft for the Carbon Border Adjustment Mechanism (CBAM), expanding the tax scope from raw materials like steel and aluminum to downstream assembled products, including automotive parts (where steel and aluminum account for over 50%), home appliances (over 30%), and gardening tools (over 20%). The implementation will occur in three phases: starting from October 2023, a transition period for data reporting; in January 2025, the declaration will open; and by January 2026, full payment obligations will be implemented. The fees will be calculated as (emissions - free allowances) × carbon price - already paid costs. Sellers are advised to self-check their products, build green supply chains, and establish compliance databases.

According to Securities Star, as shown by the Tianyancha APP, Lepu Medical (300003.SZ) has made a new external investment, with the invested company being Lepu Biotechnology Co., Ltd. The legal representative is Pu Zhongjie, and the investment share is 13.17%. The company is engaged in pharmaceutical manufacturing and has a registered capital of 1,804,439,838 RMB. Currently, Lepu Medical has a total of 74 external investments.

An investor asked on the investor interaction platform: In the field of high-end polyether applications, emerging sectors such as new energy vehicles and photovoltaics have a strong demand for special polyethers, driving an annual growth rate of over 12% in demand for special polyethers. Moreover, the industry is increasing its R&D on low unsaturation polyethers, electronic-grade polyethers, and medical polyethers to meet the stringent requirements of the downstream, such as zero detection of harmful substances and compliance with bio-based content standards. Does the company have special polyethers used in photovoltaics, medical, and other fields? Longhua New Material (301149.SZ) stated on the investor interaction platform on December 4 that end amino polyether products can be used as curing agents for epoxy resins, decorative glue (hard glue) curing agents, wind turbine blade glue curing agents, polyamide hot melt adhesive, electronic sealing glue curing agents, electronic potting materials curing agents, electronic encapsulation materials curing agents, rapid curing RIM, construction structural glue curing agents, polyether amine modified curing agents, heavy-duty anti-corrosion coating curing agents, and curing agents for composite materials such as fishing rods, golf clubs, and tennis rackets. The company's polyether products can be applied in polyurethane fiberglass composite materials and in the photovoltaic frame sector. Currently, the technology is still being promoted, and specific application scenarios are determined by downstream customers based on their own needs.

On November 24, according to foreign media reports, Tesla CEO Elon Musk recently posted on social media that the company's AI5 chip is nearing the final design stage, and work has begun on the next-generation AI6 chip to be deployed in vehicles and data centers. The world's richest man stated, "Our goal is to achieve mass production of a new generation of AI chips every 12 months. The current onboard chip is the AI4 version, the AI5 is about to complete tape-out, and we have now initiated the development of AI6." In July this year, Samsung Electronics announced that it had secured a $16.5 billion contract to produce AI chips for Tesla. Musk revealed at the time that Samsung's new factory in Texas would be dedicated to the production of AI6 chips. "We expect the total number of chips produced will surpass that of all other AI chips combined," Musk emphasized, "This is no exaggeration."

On September 26, according to CCTV News, on September 25 local time, U.S. President Trump announced on his social media platform "Truth Social" that starting from October 1, the United States will implement a new round of high tariffs on various imported products. The measures include a 50% tariff on kitchen cabinets, bathroom sinks, and related building materials, a 30% tariff on imported furniture, and a 100% tariff on patented and branded drugs.

QichachaThe APP shows that recently,Shanghai Minwei Biotechnology Co., Ltd.Business changes occurred, additions were made.Guangxi Tencent Venture Capital Co., Ltd.To the shareholders, the registered capital will be increased to approximately 16.16 million yuan.QichachaThe information shows that the company was established in 2021, with Zhang Bingfeng as the legal representative. Its business scope includes technology development in the fields of biotechnology and medical technology, and its major shareholder is...Lepu MedicalPublic information shows that the company focuses on cutting-edge "multi-core macromolecular biopharmaceutical" innovation and platform development, aiming to create innovative drugs with global competitiveness.

A team from Linköping University in Sweden has developed artificial neurons made from conductive plastic, capable of simulating the advanced functions of biological neurons while exhibiting up to 17 key characteristics. The relevant findings were published in a recent issue of the journal "Science Advances." This breakthrough in artificial neurons opens up vast prospects for a new generation of implantable sensors, medical devices, and advanced robotics technology.

Toray announced that it officially began sales in the United States in July of a new catheter for the treatment of aortic valve stenosis. The company has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its “Inoue Balloon for Aortic Valve” catheter for balloon aortic valvuloplasty, and is marketing it in the U.S. under the name “INOUE BALLOON A.” Toray has been selling catheters for mitral valve stenosis in the United States for over 30 years, and this newly launched catheter is the company’s next product line following that. The Inoue Balloon for aortic valves has been sold in Japan since 2018, and has achieved a cumulative usage of over 10,000 units in medical institutions.

Apple Inc. announced on September 11 local time that its hypertension detection system for the smartwatch has been approved by the U.S. Food and Drug Administration and will be officially launched next week. This feature will be compatible with Apple Watch Series 9, Series 10, Series 11, Ultra 2, and Ultra 3 models.

Recently, Avantium announced that it has signed a capacity reservation agreement with BIOVOX, a pioneer in sustainable healthcare plastics. Under this agreement, BIOVOX commits to using Avantium's PEF (polyethylene furanoate) for various pharmaceutical applications. This PEF is expected to be produced in future industrial-scale facilities, and the multi-year capacity reservation ensures that BIOVOX has priority access to PEF produced in Avantium's future authorized network.As a supplier of medical-grade renewable polymers and compounds, BIOVOX has assessed the use of PEF in various pharmaceutical and medical applications. Compared to traditional petrochemical-based materials, pharmaceutical packaging based on PEF offers significant environmental benefits, aligning with the growing demand for sustainable solutions in the pharmaceutical industry.

On May 22nd, as the convoy of containers carrying the first batch of medical packaging products for export to Australia set off with a whistle, Haichang Medplas officially embarked on a new chapter of its internationalization strategy, achieving a "zero breakthrough" for Shanghai Pharmaceutical's pharmaceutical packaging materials in the mainstream international market. The smooth delivery of this first order to Australia marks the entry of Haichang Medplas' internationalization strategy into a substantive advancement phase. In the face of intense competition, Haichang Medplas has strategically positioned itself internationally with forward-looking vision and efficient execution. By successfully obtaining the U.S. FDA-DMF filing number in 2023, the company significantly enhances its international competitiveness, laying a solid foundation for Haichang Medplas to further expand into international markets.

According to the China Trade Remedy Public Information Network, on May 20, 2025, the United States International Trade Commission (ITC) voted to initiate a Section 337 investigation into certain balloon dilation devices, systems, and components. The investigation code is 337-TA-1449. The named respondents are: Fiagon GmbH, Hennigsdorf, Germany; Fiagon AG Medical Technologies, Hennigsdorf, Germany; Fiagon NA Corporation, Austin, Tex.; Fiagon NA, LLC, Austin, Tex.; Hemostasis, LLC, White Bear Lake, Minn.

Roche recently announced that it will invest $50 billion in the United States over the next five years. These investments further strengthen Roche's already significant footprint in the U.S., where it has 13 manufacturing and 15 research and development sites in the pharmaceutical and diagnostics sectors. It is expected to create over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 positions for the building and expansion of facilities.

On April 21, Zimmer Biomet, a global leader in orthopedics (NYSE: ZBH), announced the completion of its acquisition of Paragon 28. The deal is valued at $1.2 billion (approximately 8.7 billion RMB). Paragon 28 offers a wide range of surgical products and systems covering all major areas of the foot and ankle, including fractures and trauma, deformity correction, as well as joint replacement.

Recently, Edwards Lifesciences announced that it...The world's firstThe transcatheter mitral valve replacement (TMVR) implant system Sapien M3, which accesses through the femoral vein, has received European CE certification. It is understood that Sapien M3 is an innovative product for transcatheter mitral valve replacement, mainly consisting of a fixation base and the SAPIEN M3 valve. The approved indication covers this procedure.Patients with moderate-to-severe and severe mitral regurgitation (MR)These patients cannot tolerate open chest surgery or transcatheter edge-to-edge repair (TEER) treatment.

On April 16th local time, Abbott announced its financial results for the first quarter of 2025. The report shows that Abbott's net sales in the first quarter reached 10.36 billion US dollars, a year-on-year increase of 4%. Among them, the medical device segment has the highest proportion, with revenue of 4.895 billion US dollars, a year-on-year increase of 9.9%; the nutrition business revenue was 2.146 billion US dollars, a year-on-year increase of 3.8%; the generic drug business revenue was 1.26 billion US dollars, a year-on-year increase of 2.7%; the diagnostic business was affected by the decline in demand for COVID-19 testing, with a year-on-year decrease of 7.2%, but excluding this factor, the organic growth turned positive to +0.5%.

On April 16, Illumina. The company announced via internal email a global workforce reduction of approximately 3.5% to advance the goal of reducing expenses by $100 million. Based on the employee count of 8,970 at the end of 2024, this round of layoffs will affect...Over 300 people。

On April 16th, global medical device giant Abbott disclosed in a financial report conference call that it expects this year's tariff policies to have an impact of "several hundred million dollars" on the company. Although Abbott did not provide details of the tariff costs, Vijay Kumar, an analyst at the globally renowned investment bank Evercore ISI, estimates that this year's tariffs will bring about $300 million to Abbott. (approximately RMB2.2 billion coinsNegative effects.Among them, the US and Chinese markets will be the main pressure zones. Reuters reported that,China is a major source of raw materials for the pharmaceutical and medical device industries.

On April 15th local time, healthcare giant Johnson & Johnson warned in its financial report that tariffs are expected to result in a $400 million profit loss for the company by 2026, with the medical device division being hit the hardest. "This $400 million loss encompasses several tariff impacts, including import tariffs beyond the scope of the North American Free Trade Agreement from Canada and Mexico, as well as global steel and aluminum tariffs (the latter having a relatively smaller impact). However, tariffs between China and the US undoubtedly account for the largest portion, with products exported from the US to China facing the most significant impact," Volk added.